DHS 75.15(11)(j)1.1. The service physician shall review the status of every patient provided with take-home medication at least every 90 days and more frequently if clinically indicated.
DHS 75.15(11)(j)2.
2. The service treatment team shall review the merits and detriments of continuing a patient's take-home privilege and shall make appropriate recommendations to the service physician as part of the service physician's 90-day review.
DHS 75.15(11)(j)3.
3. Service staff shall use biochemical monitoring to ensure that a patient with take-home privileges is not using illicit substances and is consuming the FDA-approved narcotic provided.
DHS 75.15(11)(j)4.
4. Service staff may not recommend denial or rescinding of a patient's take-home privilege to punish the patient for an action not related to meeting requirements for take-home privileges.
DHS 75.15(11)(k)
(k)
Reduction of take-home privileges or requirement of more frequent visits to the service. DHS 75.15(11)(k)1.1. A service may reduce a patient's take-home privileges or may require more frequent visits to the service if the patient inexcusably misses a scheduled appointment with the service, including an appointment for dosing, counseling, a medical review or a psychosocial review or for an annual physical or an evaluation.
DHS 75.15(11)(k)2.
2. A service may reduce a patient's take-home privileges or may require more frequent visits to the service if the patient shows positive results in drug test analysis for morphine-like substances or substances of abuse or if the patient tests negative for the narcotic drug administered or dispensed by the service.
DHS 75.15(11)(L)
(L)
Reinstatement. A service shall not reinstate take-home privileges that have been revoked until the patient has had at least 3 consecutive months of tests or analyses that are neither positive for morphine-like substances or substances of abuse or negative for the narcotic drug administered or dispensed by the service, and the service physician determines that the patient is responsible in handling narcotic drugs.
DHS 75.15(11)(m)1.1. A patient receiving a 6-day supply of take-home medication who has a test or analysis that is confirmed to be positive for a substance of abuse or negative for the narcotic drug dispensed by the service shall be placed on clinical probation for 3 months.
DHS 75.15(11)(m)2.
2. A patient on 3-month clinical probation who has a test or analysis that is confirmed to be positive for a substance of abuse or negative for the narcotic drug administered or dispensed by the service shall be required to attend the service at least twice weekly for observation of the ingestion of medication, and may receive no more than a 3-day take-home supply of medication.
DHS 75.15(11)(n)
(n)
Employment-related exception to 6-day supply. A patient who is employed and working on Saturdays may apply for an exception to the dosing requirements if dosing schedules of the service conflict with working hours of the patient. A service may give the patient an additional take-home dose after verification of work hours through pay slips or other reliable means, and following approval for the exception from the state methadone authority.
DHS 75.15(12)(a)(a) A service may grant an exception to certain take-home requirements for a particular patient if, in the reasonable clinical judgment of the program physician, any of the following conditions is met:
DHS 75.15(12)(a)1.
1. The patient has a physical disability that interferes with his or her ability to conform to the applicable mandatory schedule. The patient may be permitted a temporarily or permanently reduced schedule provided that she or he is found under
par. (c) to be responsible in handling narcotic drugs.
DHS 75.15(12)(a)2.
2. The patient, because of an exceptional circumstance such as illness, personal or family crisis, travel or other hardship, is unable to conform to the applicable mandatory schedule. The patient may be permitted a temporarily reduced schedule, provided that she or he is found under
par. (c) to be responsible in handling narcotic drugs.
DHS 75.15(12)(b)
(b) The program physician or program personnel supervised by the program physician shall record the rationale for an exception to an applicable mandatory schedule in the patient's case record. If program personnel record the rationale, the physician shall review, countersign and date the rationale in the patient's record. A patient may not be given more than a 14-day supply of narcotic drugs at one time.
DHS 75.15(12)(c)
(c) The service physician's judgment that a patient is responsible in handling narcotic drugs shall be supported by information in the patient's case file that the patient meets all of the following criteria:
DHS 75.15(12)(c)1.
1. Absence of recent abuse of narcotic or non-narcotic drugs including alcohol.
DHS 75.15(12)(c)5.
5. Stability of the patient's home environment and social relationships.
DHS 75.15(12)(c)7.
7. Assurance that take-home medication can be safely stored within the patient's home.
DHS 75.15(12)(c)8.
8. The rehabilitative benefit to the patient derived from decreasing the frequency of attendance outweighs the potential risks of diversion.
DHS 75.15(12)(d)1.1. Any exception to the take-home requirements exceeding 2 times the amount in that phase is subject to approval of the designated federal agency and the state methadone authority. The following is the amount of additional take-home doses needing approval: Phase 1 = 2 additional (excluding Sunday); phase 2 = 4 additional; phase 3 = 6 additional; phase 4 = 12 take-home doses required for approval.
DHS 75.15(12)(d)2.
2. Service staff on receipt of notices of approval or denial of a request for an extension from the state methadone authority and the designated federal agency shall place the notices in the patient's case record.
DHS 75.15(12)(e)
(e) Service staff shall review an exception when the conditions of the request change or at the time of review of the treatment plan, whichever occurs first.
DHS 75.15(12)(f)
(f) An exception shall remain in effect only as long as the conditions establishing the exception remain in effect.
DHS 75.15(13)(a)1.1. A service shall use drug tests and analyses to determine the presence in a patient of opiates, methadone, amphetamines, cocaine or barbiturates. If any other drug has been determined by a service or the state methadone authority to be abused in that service's locality, a specimen shall also be analyzed for that drug. Any laboratory that performs the testing shall comply with
42 CFR Part 493.
DHS 75.15(13)(a)2.
2. A service shall use the results of a drug test or analysis on a patient as a guide to review and modify treatment approaches and not as the sole criterion to discharge the patient from treatment.
DHS 75.15(13)(a)3.
3. A service's policies and procedures shall integrate testing and analysis into treatment planning and clinical practice.
DHS 75.15(13)(b)
(b)
Drawing blood for testing. A service shall determine a patient's drug levels in plasma or serum at the time the person is admitted to the service to determine a baseline. The determinations shall also be made at 3 months, 6 months and annually subsequently. If a patient requests and receives doses above 100 milligrams, serum levels shall be drawn to evaluate peak and trough determinations after the patient's dose is stabilized.
DHS 75.15(13)(c)
(c)
Obtaining urine specimens. A service shall obtain urine specimens for testing from a patient in a clinical atmosphere that respects the patient's confidentiality, as follows:
DHS 75.15(13)(c)1.
1. A urine specimen shall be collected upon each patient's service visit and specimens shall be tested on a random basis.
DHS 75.15(13)(c)2.
2. The patient shall be informed about how test specimens are collected and the responsibility of the patient to provide a specimen when asked.
DHS 75.15(13)(c)3.
3. The bathroom used for collection shall be clean and always supplied with soap and toilet articles.
DHS 75.15(13)(c)4.
4. Specimens shall be collected in a manner that minimizes the possibility of falsification.
DHS 75.15(13)(c)5.
5. When service staff must directly observe the collection of a urine sample, this task shall be done with respect for patient privacy.
DHS 75.15(13)(d)1.1. Service staff shall discuss positive test results with the patient within one week after receipt of results and shall document them in the patient's case record with the patient's response noted.
DHS 75.15(13)(d)2.
2. The service shall provide counseling, casework, medical review and other interventions when continued use of substances is identified. Punishment is not appropriate.
DHS 75.15(13)(d)3.
3. When there is a positive test result, service staff shall allow sufficient time before retesting to prevent a second positive test result from the same substance use.
DHS 75.15(13)(d)4.
4. Service staff confronted with a patient's denial of substance use shall consider the possibility of a false positive test.
DHS 75.15(13)(d)5.
5. Service staff shall review a patient's dosage and shall counsel the patient when test reports are positive for morphine-like substances and negative for the FDA-approved narcotic treatment.
DHS 75.15(13)(e)
(e)
Monitoring of test reports. A service shall monitor test reports to do all of the following:
DHS 75.15(13)(e)2.
2. Discover trends in substance use that may require a redirection of clinical resources.
DHS 75.15(13)(e)3.
3. Ensure that staff appropriately address with the patient a positive test report within one week after the report is received and that the report and the patient's response is documented in the patient's case record.
DHS 75.15(13)(f)1.1. The frequency that a service shall require drug screening shall be clinically appropriate for each patient and allow for a rapid response to the possibility of relapse.
DHS 75.15(13)(f)2.
2. A service shall arrange for drug screens with sufficient frequency so that they can be used to assist in making informed decisions about take-home privileges.
DHS 75.15(14)(a)(a) Patient retention shall be a major objective of treatment. The service shall do all of the following to retain patients for the planned course of treatment:
DHS 75.15(14)(a)2.
2. Render treatment in a way that is least disruptive to the patient's travel, work, educational activities, ability to use supportive services and family life.
DHS 75.15(14)(a)5.
5. Ensure that a patient has ready access to staff, particularly to the patient's primary counselor.
DHS 75.15(14)(a)6.
6. Ensure that staff are adequately trained and are sensitive to gender-specific and culture-specific issues.
DHS 75.15(14)(a)7.
7. Provide services that incorporate good practice standards for substance abuse treatment.
DHS 75.15(14)(a)8.
8. Ensure that patients receive adequate doses of narcotic medication based on their individual needs.
DHS 75.15(14)(a)9.
9. Ensure that the attitude of staff is accepting of narcotic addiction treatment.
DHS 75.15(14)(a)10.
10. Ensure that patients understand that they are responsible for complying with all aspects of their treatment, including participating in counseling sessions.
DHS 75.15(14)(b)
(b) Since treatment duration and retention are directly correlated to rehabilitation success, a service shall make a concerted effort to retain patients within the first year following admission. Evidence of this concerted effort shall include written documentation of all of the following:
DHS 75.15(14)(b)4.
4. Continued treatment is medically necessary in the professional judgement of the service physician.
DHS 75.15(14)(c)
(c) A service shall refer an individual discharged from the service to a more suitable treatment modality when further treatment is required or is requested by that person and cannot be provided by the service.
DHS 75.15(14)(d)
(d) For services needed by a patient but not provided by the service, the service shall refer the individual to an appropriate service provider.
DHS 75.15(15)
(15) Multiple substance use and dual diagnosis treatment. DHS 75.15(15)(a)(a)
Assessment. A service shall assess an applicant for admission during the admission process and a patient, as appropriate, to distinguish substance use, abuse and dependence, and determine patterns of other substance use and self-reported etiologies, including non-prescription, non-therapeutic and prescribed therapeutic use and mental health problems.
DHS 75.15(15)(b)1.1. A service shall provide a variety of services that support cessation by a patient of alcohol and prescription and non-prescription substance abuse as the desired goal.
DHS 75.15(15)(b)2.
2. Service objectives shall indicate that abstinence by a patient from alcohol and prescription and non-prescription substance abuse should extend for increasing periods, progress toward long-term abstinence and be associated with improved life functioning and well-being.
DHS 75.15(15)(b)3.
3. Service staff shall instruct multiple substance use patients about their vulnerabilities to cross-tolerance, drug-to-drug interaction and potentiation and the risk of dependency substitution associated with self-medication.
DHS 75.15(15)(c)1.1. A service shall have the ability to provide concurrent treatment for a patient diagnosed with both a mental health disorder and a substance use disorder. The service shall arrange for coordination of treatment options and for provision of a continuum of care across the boundaries of physical sites, services and outside treatment referral sources.
DHS 75.15(15)(c)2.
2. When a dual diagnosis exists, a service shall develop with the patient a treatment plan that integrates measures for treating all alcohol, drug and mental health problems. For the treatment of a dually-diagnosed patient, the service shall arrange for a mental health professional to help develop the treatment plan and provide ongoing treatment services. The mental health professional shall be available either as an employee of the service or through a written agreement.
DHS 75.15(16)(a)(a) A service that provides narcotic addiction treatment to pregnant women shall provide that treatment within a comprehensive treatment service that addresses medical, prenatal, obstetrical, psychosocial and addiction issues.
DHS 75.15(16)(b)
(b) A diagnosis of opioid addiction and need of the patient to avoid use of narcotic antagonists shall be based on the same factors, such as medical and substance abuse history, psychosocial history, physical examination, test toxicology and signs and symptoms of withdrawal, that are used in diagnosing opiate addiction in non-pregnant opioid-dependent women. In this paragraph, "narcotic antagonist" means a drug primarily used to counter narcotic-induced respiratory depression.
DHS 75.15(16)(c)
(c) A pregnant woman seeking narcotic addiction treatment shall be referred to a perinatal specialist or obstetrician as soon as possible after initiating narcotic addiction treatment with follow up contact, to coordinate care of the woman's prenatal health status, evaluate fetal growth and document physiologic dependence.
